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Background: Despite the importance of inflammation in cancer, the role of the cytokine IL-33, and its receptor ST2, in colon
cancer is unclear. The aim of this study was to investigate the role of IL-33, and its receptor isoforms (ST2 and ST2L), in colon
cancer.
Methods: Serum levels of IL-33 and sST2 were determined with ELISA. ST2 and IL-33 expression was detected with quantitative
real-time PCR (qRT–PCR), western blotting and immunohistochemistry. ST2 expression in CT26 cells was stably suppressed using
ST2-specific shRNA. Cytokine and chemokine gene expression was detected with qRT–PCR.
Results: Human colon tumours showed lower expression of ST2L as compared with adjacent non-tumour tissue (Po0.01).
Moreover, the higher the tumour grade, the lower the expression of ST2L (P¼ 0.026). Colon cancer cells expressed ST2 and IL-33
in vitro. Functional analyses showed that stimulation of tumour cells with IL-33 induced the expression of chemokine (C–C motif)
ligand 2 (CCL2). Knockdown of ST2 in murine colon cancer cells resulted in enhanced tumour growth (Po0.05) in BALB/c mice
in vivo. This was associated with a decrease in macrophage infiltration, with IL-33-induced macrophage recruitment reduced by
antagonising CCL2 in vitro.
Conclusion: The IL-33/ST2 signalling axis may have a protective role in colon carcinogenesis.
Interleukin (IL)-33 is a member of the IL-1 superfamily, identified
in 2005 as the ligand for the receptor ST2. Differential mRNA
processing within the ST2 gene generates three isoforms of ST2
proteins: a transmembrane receptor (ST2L), a secreted soluble
form (sST2) and a variant form (ST2V; Garlanda et al, 2013).
Initial studies on the role of ST2L in the immune system
demonstrated that ST2L is expressed on many immune cells,
including macrophages, mast cells, innate lymphoid cells and T
cells, in particular Th2 cells (Lu et al, 2015). Moreover, signalling
through ST2L promotes the development of Th2 cells, and the
induction of the Th2 cytokines IL-4, IL-5 and IL-13. sST2 is
thought to act as a decoy receptor, binding to IL-33, whereas the
function of ST2V is unclear. More recently, research on IL-33/ST2
has predominantly focused on their role in chronic disorders, with
IL-33 and ST2 involved a role in the pathogenesis of several human
inflammatory diseases including inflammatory bowel disease
(Pastorelli et al, 2010; Sedhom et al, 2013).
Given the importance of inflammation in cancer, recent studies
have begun to investigate the role of IL-33 and ST2 in
carcinogenesis. Interleukin-33 has been shown to be elevated in
the serum of patients with cancer, including that of gastric, lung
and hepatocellular cancer patients (Chen et al, 2014), with high
levels of sST2 detected in the serum of metastatic breast cancer
(Gillibert-Duplantier et al, 2012) and hepatocellular cancer patients
(Bergis et al, 2013). Studies in breast cancer have suggested that the
IL-33/ST2 pathway inhibits antitumour immunity, subsequently
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promoting breast cancer metastasis (Jovanovic et al, 2014). Other
studies have implicated a role for IL-33 and ST2 in tumour cell
invasion and metastasis, with inhibition of IL-33 in glioma cells
and colon cancer cells resulting in reduced tumour growth,
migration and colony formation in vitro, and smaller tumours
in vivo (Fang et al, 2014; Liu et al, 2014). Interleukin-33 was also
shown to activate tumour stroma and promote polyposis in APC
(Min/þ ) mice (Maywald et al, 2015). In contrast, a protective role
for IL-33 has been reported in other studies, with IL-33 reduced in
the plasma of non-small-cell lung cancer relative to controls
(Barrera et al, 2015), and IL-33 negatively correlating with the
tumour stage in multiple myeloma patients (Musolino et al, 2013).
Moreover, whereas expression of both IL-33 and ST2 was shown to
be increased in intestinal adenomas, expression of both proteins
was reduced in colorectal carcinomas (Cui et al, 2015). Moreover,
overexpression of IL-33 in tumours resulted in an increase in the
antitumour immune response and tumour rejection through the
activation of CD8þ T cells and natural killer (NK) cells (Gao et al,
2015). Most studies to date, however, have focused predominantly
on the role of IL-33 in cancer, with less known about the role of the
receptor. Here we demonstrate that suppression of ST2 expression
by colon tumour cells results in increased tumour growth in vivo,
with progressively lower expression of ST2L by tumour cells
observed with increasing tumour stage.
MATERIALS AND METHODS
Study populations. The study protocol, including all procedures
and study populations, was approved by the University College
Cork Clinical Research Ethics Committee of the Cork Teaching
Hospitals (ECM (3) P 3 September 2013). For patient cohort 1, 24
fresh samples of human colon cancer and paired normal tissues
were obtained during surgery at the Mercy University Hospital
Cork. A blood sample was obtained from each patient before
surgery for serum analysis. All samples were collected with
patients’ informed consent. For patient cohort 2, 68 paraffin-
embedded formalin-fixed samples were obtained from the archives
of Cork University Hospital. Relevant patient history was also
extracted from the archives. Control serum samples were obtained
from healthy volunteers aged between 18 and 65 years. Patient
demographics are contained in Supplementary Table 1.
Reagents. Recombinant TNFa was obtained from PeproTech
(Rocky Hill, NJ, USA), EGF was purchased from Biolegend Inc
(San Diego, CA, USA) and PGE2 was obtained from Cayman
Company (Ann Arbor, MI, USA). LPS was purchased from
Invivogen (San Diego, CA, USA). Recombinant IL-33 was obtained
from ProSpec (East Brunswick, NJ, USA). The primary antibodies
used were as follows: polyclonal anti-human anti-ST2L antibody
(cat # NBP1-85251) Novus, (Littleton, CO, USA), anti-mouse anti-
ST2 antibody (cat#ab25877) Abcam (Cambridge, UK), anti-human
anti-IL-33 antibody (Nessy-1) (cat#ALX-804-840) Enzo Life
Sciences (Farmingdale, NY, USA). APC/Cy7 anti-mouse Ly-6G/
Ly-6C antibody and PE anti-mouse F4/80 antibody were obtained
from Biolegend Inc. FITC rat anti-mouse CD8 was purchased from
BD Biosciences (Franklin Lakes, NJ, USA).
Mice and tumour model. Female BALB/c mice (4–6 weeks) were
obtained from Harlan UK (Oxon, UK) and experiments performed
in accordance with the institutional guidelines using an Animal
Experimentation Ethics Committee-approved protocol (approval
2012/051). To establish subcutaneous tumours, mice were injected
into the right flank with 4.0 104 CT26 cells resuspended in 200 ml
phosphate-buffered saline (five mice per group). Tumour growth
was monitored by regular measurement of tumour length (a) and
width (b) using a Vernier calliper, and the volume was calculated as
follows: ½ (a b2). Animals were killed 20 or 24 days later and
tumours excised. The acceptable maximum tumour volume for
mice to be killed was 2 cm3, in accordance with the ethical
guidelines.
Generation of ST2Low/negative CT26 cells. Cells were transfected
with lentiviral particles containing target-specific shRNAs against
ST2 (sc-40036-V) or control lentiviral particles containing
scrambled shRNA (sc-108080; Santa Cruz Biotechnology, Dallas,
TX, USA), according to the manufacturers’ instructions. Puromy-
cin-resistant clones were selected by limiting dilution.
Quantitative real-time PCR. Total RNA was isolated using the
GenElute Mammalian Total RNA Mini kit (Sigma-Aldrich, Dorset,
UK) according to the manufacturer’s instructions, and cDNA was
synthesised. Individual PCR primer pairs (Supplementary Table 2)
and probes were designed using the Roche Universal Probe Library
Assay Design Centre. The 2DDCT method was used to calculate
relative changes in the gene expression.
Immunohistochemistry. Immunohistochemical staining was per-
formed on formalin-fixed, paraffin-embedded (FFPE) sections as
previously described (Fernandes et al, 2015). A semiquantitative
scoring system was developed, with each tumour given a score
according to the intensity of staining.
Proliferation assay. Cell proliferation was determined by
analysing BrdU incorporation into newly synthesised DNA
using a Cell Proliferation ELISA System (Roche Molecular
Biochemicals, Mannheim, Germany) according to the manufac-
turer’s instructions.
Flow cytometry. Single-cell suspensions were prepared by col-
lagenase/dispase digestion. Overall, 200 000 cells were re-sus-
pended in 200 ml of cell-staining buffer, incubated with antibodies
to LY6G, CD8 or F4/80 for 30 min at 4 1C in the dark, and then
fixed in 1% paraformaldehyde. Relative fluorescence intensities
were measured using a FACSLSRII 5 laser (UV/violet/blue/
yellowgreen/red) cytometer and BD Diva software (Becton
Dickinson, Oxford, UK). For each sample, 20 000 events were
recorded. Dead cells were gated out of the analysis by staining with
the viability dye VIVID (Invitrogen). The percentage of cells
labelled with each antibody was calculated in comparison with cells
stained with isotype control antibody. Analysis gates for each
antibody were set by using fluorescence minus one controls with a
threshold below 1% (Supplementary Figure 3).
Statistical analysis. Experiments were performed a minimum
of three times in triplicate. Results were statistically evaluated
using one-way ANOVA with Dunnetts post test, or by Student’s
paired t-test. The Kendall tau-b correlation coefficient was used
to evaluate the association between ST2L expression and tumour
stage. Kaplan–Meier analysis was used to calculate survival
rates, and differences in survival curves were determined by the
log-rank test.
RESULTS
Expression of ST2L in CRC is lower compared with adjacent
non-tumour tissue, with expression being progressively lower
with higher tumour grade. In order to examine potential
alterations in expression of both IL-33 and its receptor ST2 in
colorectal cancer stage (CRC), a cohort of 24 patients with CRC
was recruited, 8 of whom had received chemotherapy before
surgery. Initially, expression levels of IL-33 and ST2 were examined
using quantitative real-time PCR (qRT–PCR). There was no
change in the level of transcription of either IL-33 or total ST2
between CRC and adjacent non-tumour tissue (Figure 1A). We
subsequently designed and utilised a primer specific to the
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intracellular portion of ST2 to examine changes in expression of
ST2L in colon cancer. The level of ST2L mRNA was significantly
lower (P¼ 0.0067) in CRC tissue as compared with adjacent non-
tumour tissue (Figure 1A). Alterations in expression were
confirmed at the protein level using immunohistochemistry
(IHC). No change was observed in either IL-33 or total ST2,
although staining intensity for ST2L was consistently lower in CRC
as compared to adjacent non-tumour tissue. Representative images
are shown in Figure 1B. Serum levels of IL-33 and sST2 were also
examined in CRC patients (n¼ 24) compared with healthy
volunteers (n¼ 15), with a slight decrease in IL-33 (P¼ 0.0252)
and no alterations of sST2 (Figure 1C) observed.
We subsequently wished to identify whether there was any
association between expression of ST2L and tumour grade. To
investigate this, IHC for ST2L was performed on 68 FFPE tissue
sections of various stages of CRC, 17 of whom had received
chemotherapy. A scoring system was developed, with the staining
intensity of ST2L categorised as negative, weak, moderate or
strong. As the tumour stage increased, the intensity of ST2L
expression observed was lower, with expression of ST2L negatively
correlating with tumour grade (Kendall tau-b:  0.248, P¼ 0.026).
Fifty-seven per cent of stage I tumours showed moderate to strong
expression, with only 15% of stage IV tumours showing moderate/
strong expression (Table 1). Representative images of the ST2L
staining obtained for each stage are shown in Figure 2A.
The relationship between the expression levels of ST2L and
clinical prognosis in cohort 2 was also assessed. Clinicopathological
correlation for these patients was evaluated by determining the
patients’ survival and clinical progression. There was a trend
towards improved overall survival when tumours had strong to
moderate expression of ST2L, although this was not statistically
significant (P¼ 0.0838; Figure 2B).
No association was observed between ST2L expression and
chemotherapy treatment. Approximately half of the samples
derived from patients receiving chemotherapy were negative for
ST2L (9 out of 17) and (5 out of 8), with the remainder all
expressing ST2L of varying intensities.
Colon cancer cell lines express ST2L and IL-33, with IL-33
stimulation not increasing cell proliferation or invasion, but
inducing migration in vitro. To further characterise and examine
the role of ST2 and IL-33 in colon cancer, expression of both ST2L
and IL-33 was examined in several colon cancer cell lines. Basal
expression of ST2L was low in all three cell lines examined, with
expression increased upon stimulation with the pro-inflammatory
stimuli, LPS, TNFa and PGE2 (Figure 3A). Interleukin-33 protein
was also detected in all cell lines, with no change in expression seen
upon stimulation with any of the pro-inflammatory cytokines
investigated (Figure 3A). In contrast, IL-33 was expressed at a very
low basal level in both B16F10 melanoma and A549 lung cancer
cells, with expression induced upon stimulation with LPS. More-
over, these cells had high basal levels of ST2L, which was unaltered











































































































Figure 1. ST2L expression is lower in colorectal cancer tissue relative to adjacent non-tumour tissue. (A) RNA was extracted and changes in IL-33,
total ST2 and ST2L detected using qRT–PCR. (B) Immunohistochemical staining for IL-33, ST2 and ST2L was performed on paraffin-embedded
tissue sections. Original magnification: 20. Images shown are representative of the findings obtained. (C) Serum was obtained from healthy
individuals and patients with CRC, and IL-33 and sST2 levels determined using ELISA.
Table 1. ST2L expression in colon tumour cells
CRC stage Total % Negative/weak % Moderate/strong
Stage I 14 43 57
Stage II 21 62 38
Stage III 20 65 35
Stage IV 13 85 15
Abbreviation: CRC= colorectal cancer stage. Expression of ST2L decreases with increasing
tumour stage. Tumour sections were scored as negative, weak, moderate or strong,
according to the intensity of ST2L staining. Kendall tau-b:  0.248, P¼ 0.026.
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Colon cancer cells were stimulated with increasing concentra-
tions of IL-33 and changes in proliferation and migration
examined. Interleukin-33 treatment resulted in a slight decrease
in cellular proliferation (Figure 3B). In contrast, IL-33 increased
the migration of the cells over the levels observed towards 10%
serum. This increase in migration occurred in a dose-dependent
manner for all cell lines (Figure 3C). Interleukin-33, however, had
no effect on cell invasion (Figure 3D).
Interleukin-33 induces limited expression of cytokines/
chemokines in colon cancer cells. As we had observed expression
of ST2L in unstimulated cells, we next investigated whether IL-33
induced the transcription of cytokines, chemokines or angiogenic
factors. Stimulation of HT29 (Figure 4A) and SW480 (Figure 4B)
human colon cancer cells with IL-33 had no effect on transcription
of a panel of factors, with the exception of CCL2, which was






















(i) (ii) (iii) (iv)
Figure 2. ST2L expression is progressively lower with increasing tumour stage. (A) Immunohistochemical staining for ST2L was performed on
paraffin-embedded colonic tissue sections. Original magnification: 20. Images shown are representative of the findings obtained for each stage.
(B) The relationship between ST2L expression in CRC cells and clinical prognosis in patients with CRC was analysed by Kaplan–Meier analysis.










































































































0 15 30 60
+
0 15 30 60 IL-33 (ng ml–1)
EGF (100 ng ml–1)+
0




Figure 3. Pro-inflammatory cytokines induce the expression of ST2L but not IL-33 in colon cancer cells, with IL-33 inducing migration but not
proliferation or invasion in vitro. (A) Cells were stimulated for 24 h with LPS, TNFa and PGE2 as indicated, and changes in ST2L and IL-33 detected.
Immunoblotting for b-actin was used as the loading control. Data shown are representative of three independent experiments. Cells were
stimulated with IL-33 as indicated and changes in (B) proliferation assessed by BrdU incorporation, with EGF used as a positive control,
(C) migration assessed using a modified Boyden chamber assay and (D) invasion assessed using a Matrigel invasion assay system. Data shown are
mean±s.e.m. (n¼ 3).
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lines, stimulation of murine CT26 cells with IL-33 induced an
increase in VEGF, CXCL-1 and CCL2 (Figure 4C).
Suppression of ST2 expression in colon cancer cells results in
increased tumour growth in vivo. We next investigated the
biological effect of reducing ST2 expression in colon cancer cells in
a murine model. ST2 expression was reduced in CT26 mouse colon
cancer cells using shRNA, the suppression of ST2 being confirmed
using western blot analysis (Figure 5A). Suppression of ST2 did not
affect either the basal level of proliferation (Figure 5B), prolifera-
tion induced by pro-inflammatory stimuli (Supplementary
Figure 2A) or migration (Figure 5C) of these cells. Consistent
with reduced expression of ST2, CT26ST2 shRNA#1 and #2 cells
showed markedly reduced transcription of CXCL-1 following IL-33
stimulation (Figure 5D). Immunocompetent BALB/c mice were
injected subcutaneously with CT26scr shRNA#1, CT26 ST2 shRNA#1 or
CT26ST2 shRNA#2 cells, and tumour growth monitored. All mice
developed palpable tumours. However, in contrast to the in vitro
findings, whereby suppression of ST2 did not alter cellular
proliferation, tumour growth was increased when ST2 was
suppressed in advance by shRNA (Figure 5E; Po0.05).
These findings were confirmed in a second independent study
using additional CT26scr shRNA#2 and CT26ST2 shRNA#3 clones that
were subsequently derived. In this second study, the increase in
tumour growth following suppression of ST2 was even more
















































































































Figure 4. IL-33 induces the expression of a limited number of cytokines/chemokines in colon cancer cells. (A–C) Cells were stimulated with
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Figure 5. Suppression of ST2 expression by colon cancer cells results in increased tumour cell growth in vivo. (A, D) ST2 expression was
suppressed in CT26 cells (CT26ST2 shRNA) and the efficiency of suppression of ST2 was assessed using (A) western blot and (D) functional analyses.
Changes in basal levels of (B) proliferation and (C) migration were assessed. (E) Cells were subcutaneously injected into BALB/c mice and tumour
growth monitored. (F–H) Tumours were excised and infiltration of Ly-6Gþ , F4/80þ and CD8þ cells assessed using flow cytometry.
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Tumours were excised and immune cells analysed using flow
cytometry. Although suppression of ST2 in tumours did not affect
neutrophil infiltration (Figure 5F), there was a reduction in
macrophage recruitment following ST2 knockdown in the tumour
cells (Figure 5G). Although not significant, there was also a
decrease in the recruitment of CD8þ T cells (Figure 5H).
Representative dot plots for the flow cytometric analysis are
shown in Supplementary Figure 3.
IL-33 induces the recruitment of macrophages in vitro, with
IL-33 expression reduced in CT26ST2shRNA-derived tumours
in vivo. It is well established that, if appropriately activated,
macrophages can mediate tumour rejection (Edin et al, 2013).
Given the reduction seen in macrophage infiltration in tumours
derived from CT26ST2 shRNA#1 and #2 cells, we investigated whether
there was an increase in macrophage migration towards super-
natant from IL-33-stimulated tumour cells, relative to untreated
tumour cell supernatant. There was an B25% increase in
migration of macrophages as compared with unstimulated CT26
cell supernatant (Figure 6A). Consistent with the induction of
CCL2 by IL-33, a blocking antibody to CCL2 reduced macrophage
migration towards the supernatant of IL-33-stimulated CT26 cells
(Po0.05; Figure 6A).
We finally examined expression of IL-33 within the murine
tumours. A marked reduction was observed in IL-33 expres-
sion within the CT26ST2 shRNA tumours as compared with
CT26Scr shRNA tumours. Although the underlying mechanism for
this reduction in IL-33 in vivo is unclear, it may be due to a lack of
positive regulation of IL-33 by ST2L signalling. In conclusion, these
data suggest that the alterations in tumour growth in vivo following
suppression of ST2 is likely due, at least in part, to a reduction
in tumour-expressed IL-33, perhaps due to a reduction in tumour-
derived macrophage chemotactic factors, and consequent
reduction in macrophage recruitment.
DISCUSSION
In this study we have demonstrated, using both a preclinical in vivo
model of tumour development involving ectopically injected colon
carcinoma cells, as well as human clinical samples, that signalling
through ST2 on tumour cells likely has an antitumorigenic role in
CRC. We have shown that suppressing ST2 expression in colon
tumour cell lines increased tumour growth in vivo. Expression of
ST2L was found to be lower in human tumours relative to adjacent
non-tumour tissue, with the higher the tumour grade, the lower the
expression of ST2L.
Several recent reports have demonstrated an antitumorigenic role
for the IL-33–ST2 axis. In these studies, IL-33 was shown to
promote the function of CD8þ T cells and NK cells, thereby
promoting tumour eradication (Yang et al, 2011). Consistent with
this, studies examining T-cell infiltration in CRC have shown that
high levels of CD8þ T-cell infiltration is associated with improved
overall patient survival (Naito et al, 1998). Macrophages can also act
as potent antitumour immune effector cells (Edin et al, 2013). In our
study, lack of ST2 expression in tumours was associated with a
reduction in both macrophage and CD8þ T cell, and augmented
tumour growth. Consistent with a potential antitumorigenic role for
ST2, we have shown that a low level of ST2 is associated with poor
prognosis and overall survival in human CRC. Thus, our data
indicate that the reduction in ST2 expression by tumour cells may
result in reduced signalling through ST2, affecting the tumour
microenvironment by altering the cell composition of the micro-
environment, favouring increased tumour growth.
Recent studies investigating the role of IL-33/ST2 in colon
cancer have shown somewhat divergent effects (Liu et al, 2014; Cui
et al, 2015; Maywald et al, 2015). In contrast to our findings, these
studies reported an increase in IL-33 in CRC as compared with
adjacent normal tissue and healthy volunteers, with IL-33 having a
protective antitumorigenic effect in CRC (Liu et al, 2014).
Interestingly, the level of IL-33 varied greatly between the studies.
Similar to our findings, the level of IL-33 seen in CRC was low in
two studies (Liu et al, 2014; Cui et al, 2015), with only Maywald
et al (2015) reporting high levels of IL-33 in tumours. However, all
patients in this study were a heavily pre-treated cohort, receiving
5-fluorouracil-based chemotherapy before analysis. As IL-33 is well
known to be released upon cellular damage, it is possible that the
chemotherapeutic regimes directly affected the levels of IL-33 in
these patients. Indeed, the low level of IL-33 seen in our study may
be reflective of the lack of prior chemotherapy in our cohorts. Total
ST2 was also reported to be increased in CRC cells relative to
adjacent normal cells, in contrast to our findings (Liu et al, 2014).
These differences could be because of the isoforms of ST2
examined, given that our observed decrease in expression of ST2
was confined to the transmembrane-bound signalling active
L-isoform (ST2L). Indeed, to the best of our knowledge, no other
study has specifically examined the expression of ST2L in CRC.
Here we have shown that ST2L expression is upregulated by
pro-inflammatory stimuli that have been implicated in colon
cancer (LPS, TNFa and PGE2), whereas IL-33 appears to be more
tightly regulated. This lack of upregulation of IL-33 may well
reflect the overall low levels of IL-33 seen in CRC tumour cells.
Further characterisation of the function of IL-33 in colon cancer
cells revealed that IL-33 did not increase cell proliferation or
invasion in vitro, but did induce cell migration. This ability of
IL-33 to induce cell migration in vitro suggests that IL-33 may be
involved in metastasis in vivo, as suggested by Liu et al (2014).







































Figure 6. Supernatant from colon cancer cells stimulated with IL-33 show enhanced macrophage migration relative to unstimulated supernatant.
(A) Supernatant was isolated from unstimulated or IL-33-stimulated CT26 cells. Neutralising CCL2 antibody was added to the supernatant as
indicated. Migration of RAW264.7 macrophages towards the cell culture supernatant was assessed with modified Boyden chamber assay. Data
shown are mean±s.e.m. (n¼3). (B) Immunohistochemical staining for IL-33 was performed on paraffin-embedded murine tumour sections.
Original magnification:  40. Images shown are representative of the findings obtained.
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at higher doses of IL-33, which may not be physiologically relevant.
Indeed, IL-33 in the serum of cancer patients, as seen both in this
study, and others, was typically in the low pg ml 1 concentration
(Sun et al, 2011; Zhang et al, 2012).
We also comprehensively characterised induction of cytokine
and chemokines by IL-33. Interleukin-33 only induced the
expression of CCL2 in human cells, with VEGF and CXCL-1 also
being induced in murine cancer cells. Other studies investigating
induction of cytokines and chemokines in non-haematopoietic
cells have also shown a similar lack of induction of cytokines/
chemokines by IL-33 (Masamune et al, 2010). This implies that the
response of non-haematopoietic cells to IL-33 stimulation is highly
restricted. Indeed, this lack of upregulation of inflammatory
cytokines and chemokines is perhaps unsurprising, given the role
of IL-33 in maintaining barrier function and homeostasis in the
gastrointestinal tract (Lopetuso et al, 2012).
In conclusion, our study has shown a potential antitumorigenic
role for ST2L in colon cancer. This is likely mediated by alterations
in immune infiltrating cells, in particular through alterations in
infiltration by macrophages and CD8þ T cells. Therefore,
targeting ST2L may have potential therapeutic benefit for the
treatment of colon cancer. However, given that IL-33 and ST2
appear to have differing and opposing functions, depending on the
cell type, tissue and organ examined, further work on the role of
IL-33 and ST2 in cancer is required.
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